- Home
- MBAI vs MCRB Comparison
MBAI vs MCRB Comparison
Compare MBAI & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBAI | MCRB |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 41.2M |
| IPO Year | 2014 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MBAI | MCRB |
|---|---|---|
| Price | $2.22 | $2.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 18.0K | ★ 68.0K |
| Earning Date | 11-08-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $789,000.00 |
| Revenue This Year | $103.86 | N/A |
| Revenue Next Year | $231.30 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $2.39 |
| 52 Week High | $10.21 | $29.98 |
Technical Indicators
Market Signals| Indicator | MBAI | MCRB |
|---|---|---|
| Relative Strength Index (RSI) | 25.63 | 24.13 |
| Support Level | $1.19 | N/A |
| Resistance Level | $3.92 | $9.53 |
| Average True Range (ATR) | 0.28 | 0.23 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 4.46 | 7.72 |
Price Performance
Historical ComparisonAbout MBAI Check-Cap Ltd. Ordinary Share
MBody AI Ltd develops enterprise software to deploy and manage autonomous robot workforces for hospitality and gaming operators. The Company's proprietary MBody AI Orchestrator is a hardware-agnostic software platform that manages diverse robot fleets from multiple vendors across sites and use cases under long-term agreements. MBody AI serves Fortune 500 operators as customers.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.